EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Early GH Treatment Is Effective and Well Tolerated in Children With Turner Syndrome: NordiNet® IOS and Answer Program

Philippe Backeljauw iD, Joanne C Blair, Jean-Marc Ferran, Nicky Kelepouris, Bradley S Miller, Alberto Pietropoli, Michel Polak, Lars Sävendahl, Franciska Verlinde, Tilman R Rohrer

The Journal of Clinical Endocrinology & Metabolism · 18.09.2023 · 108 (10) · 2653-2665

DOI: 10.1210/clinem/dgad159 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 22.03.2023. Verfasst von Philippe Backeljauw und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Endocrinology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH 4522…. Hauptthemen laut MEDLINE: Dwarfism, Pituitary, Human Growth Hormone, Turner Syndrome. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novo Nordisk.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Despite having normal growth hormone (GH) secretion, individuals with Turner syndrome (TS) have short stature. Treatment with recombinant human GH is recommended for TS girls with short stature.

Objective

This work aimed to evaluate the effectiveness and safety of Norditropin (somatropin, Novo Nordisk) with up to 10 years of follow-up in children with TS.

Methods

Secondary analysis was conducted of Norditropin data from 2 non-interventional studies: NordiNet® IOS (NCT00960128) and the ANSWER program (NCT01009905).

Results

A total of 2377 girls with TS were included in the safety analysis set (SAS), with 1513 in the treatment-naive effectiveness analysis set (EAS). At the start of treatment, 1273 (84%) participants were prepubertal (EAS); mean (SD) age was 8.8 (3.9) years. Mean (SD) dose received at the start of GH treatment was 0.045 (0.011) mg/kg/day (EAS). Mean (SD) baseline insulin-like growth factor-1 (IGF-I) SD score (SDS) was −0.86 (1.52), and mean (SD) duration of GH treatment (SAS) was 3.8 (2.8) years. Height SDS (HSDS) increased throughout follow-up, with near-adult HSDS reached by 264 (17%) participants (mean [SD] −1.99 [0.94]; change from baseline +0.90 [0.85]). During the study, 695 (46%) participants (EAS) entered puberty at a mean (SD) age of 12.7 (1.9) years (whether puberty was spontaneous or induced was unknown). Within the SAS, mean IGF-I SDS (SD) at year 10 was 0.91 (1.69); change from baseline +1.48 (1.70). Serious adverse reactions were reported in 10 participants (epiphysiolysis [n = 3]).

Conclusion

GH-treated participants with TS responded well, without new safety concerns. Our real-world data are in agreement with previous studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dwarfism, PituitaryHuman Growth HormoneTurner SyndromeAdultChildFemaleHumansBody HeightGrowth DisordersInsulin-Like Growth Factor IChild, Preschool

Stichwörter der Autor:innen

adverse reactionschildreneffectivenesshuman growth hormonesafetyturner syndrome

Substanzen

Human Growth HormoneInsulin-Like Growth Factor I

Autor:innen und Institutionen

  • Division of Pediatric Endocrinology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH 45229-3039, USA.
  • Department of Endocrinology, Alder Hey Children's NHS Foundation Trust, Liverpool L14 5AB, UK.
  • Qualiance ApS, 1663 Copenhagen V, Denmark.
  • Novo Nordisk Inc, Plainsboro, NJ 08536, USA.
  • Division of Pediatric Endocrinology, M Health Fairview Masonic Children's Hospital, Minneapolis, MN 55454, USA.
  • Novo Nordisk Health Care AG, 8050 Zurich, Switzerland.

ORCID-Profile: Philippe Backeljauw

Förderung

  • Novo Nordisk

Zitieren

APA

Backeljauw, P., Blair, J. C., Ferran, J. M., Kelepouris, N., Miller, B. S., Pietropoli, A., Polak, M., Sävendahl, L., Verlinde, F., & Rohrer, T. R. (2023). Early GH Treatment Is Effective and Well Tolerated in Children With Turner Syndrome: NordiNet® IOS and Answer Program. The Journal of Clinical Endocrinology & Metabolism, 108(10), 2653-2665. https://doi.org/10.1210/clinem/dgad159

Vancouver

Backeljauw P, Blair JC, Ferran JM, Kelepouris N, Miller BS, Pietropoli A, et al. Early GH Treatment Is Effective and Well Tolerated in Children With Turner Syndrome: NordiNet® IOS and Answer Program. The Journal of Clinical Endocrinology & Metabolism. 2023;108(10):2653-2665. doi:10.1210/clinem/dgad159

BibTeX
@article{Backeljauw2023,
  author = {Backeljauw, Philippe and Blair, Joanne C and Ferran, Jean-Marc and Kelepouris, Nicky and Miller, Bradley S and Pietropoli, Alberto and Polak, Michel and Sävendahl, Lars and Verlinde, Franciska and Rohrer, Tilman R},
  title = {Early GH Treatment Is Effective and Well Tolerated in Children With Turner Syndrome: NordiNet® IOS and Answer Program},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2023},
  volume = {108},
  number = {10},
  pages = {2653--2665},
  doi = {10.1210/clinem/dgad159}
}
Kostenlos starten →